Novel Medication as a Potential Smoking Cessation Aid

University of Minnesota (UMN)

Status: Completed

Conditions: Tobacco Use Disorder

Treatments: Drug: Placebo; Drug: Levomilnacipran

Study type: Interventional

Funder types: Other

Identifiers

NCT02265367

1409M53561

Details and patient eligibility

About

The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.

Enrollment: 56 patients

Sex: All

Ages: 25 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be between 25 years old and 55 years old
• Smoke a minimum number of cigarettes per day
• Indicate motivation to quit smoking

Exclusion criteria

• Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication
• Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran
• Are pregnant or breast feeding

The investigators will evaluate if there are other reasons why someone may not be eligible to participate

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

56 participants in 2 patient groups

Levomilnacipran

Experimental group

Description:

In the first three week period levomilnacipran is evaluated whereas in the second three week period placebo is evaluated

Treatment:

Drug: Levomilnacipran

Drug: Placebo

Placebo

Experimental group

Description:

In the first three week period placebo is evaluated whereas in the second three week period levomilnacipran is evaluated

Treatment:

Drug: Levomilnacipran

Drug: Placebo